|
Vancouver, British Columbia – June 17, 2019 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (“Sirona”) is pleased to announce that the patent for TFC-1067 entitled “Gem Difluorocompounds as Depigmenting or Lightening Agents” was granted in the USA, as expected, and will be published in the official database in the coming month. To date, the TFC-1067 skin lightening patent has been granted in Germany, France, United Kingdom and now the US. Further TFC-1067 patent applications are in the patent pending status in multiple other countries while they go through the normal approval process. TFC-1067, Sirona’s proprietary skin lightening compound, is superior to current actives on the market, safe and free of hydroquinone. The compound has undergone extensive testing, both preclinical and clinical, including a double blinded study for dyschromia in the US. Clinical results were received in late February 2019 and showed the compound to be superior to hydroquinone in the treatment of dyschromia with no adverse side effects. Sirona is currently in advanced negotiations in North America and Asia in regards to licensing rights for TFC-1067. “This patent grant in one of the largest skin care markets is another important milestone for TFC-1067. The patent application was without concern to our potential partners as determined by their IP lawyers however it is an important and exciting milestone to reach,” said Dr. Howard Verrico, CEO of Sirona Biochem. “This will allow our potential US partners’ absolute IP certainty to move forward with their product marketing plans.” The global skin lightening market is expected to reach $23 Billion USD by 2022[1]. |
|
| aus der Diskussion: | Sirona Biochem |
| Autor (Datum des Eintrages): | techinvestor69 (17.06.19 09:08:16) |
| Beitrag: | 12,746 von 31,013 (ID:60820793) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |